Healthcare


 CSL Gains FDA Nod as ASX 200 Healthcare Faces Global Pressure

CSL Gains FDA Nod as ASX 200 Healthcare Faces Global Pressure

June 20, 2025 05:21 PM AEST| By Team Kalkine Media

Highlights,CSL Limited (ASX:CSL) receives FDA clearance for rare disease treatment,Healthcare stocks within the ASX 200 and ASX 100 indices reflect cautious sentiment,External trade and policy developments influence ASX 200 healthcare performance,CSL...

 Orthocell’s Breakthrough in Nerve Repair Places It on the ASX200 Innovation Radar

Orthocell’s Breakthrough in Nerve Repair Places It on the ASX200 Innovation Radar

June 20, 2025 03:40 PM AEST| By Team Kalkine Media

Highlights,Orthocell’s Remplir outperforms traditional suture-only nerve repair methods,Interim study results support rapid U.S. product rollout,Potential to impact ASX200 medical innovation landscape,Orthocell (ASX:OCC) has unveiled encouraging inte...

 ECS Botanics (ASX:ECS) Faces Pressure Amid Revenue Concerns | All Ordinaries Spotlight

ECS Botanics (ASX:ECS) Faces Pressure Amid Revenue Concerns | All Ordinaries Spotlight

June 20, 2025 03:03 PM AEST| By Team Kalkine Media

Highlights,ECS Botanics Holdings Ltd shares decline amid shrinking revenue performance,Valuation metrics reflect subdued expectations compared to pharmaceutical peers,Broader All Ordinaries index maintains contrast with ECS’s sectoral challenges,ECS...

 Arovella Therapeutics Extends Momentum on ASX 200 with Continued Growth Streak

Arovella Therapeutics Extends Momentum on ASX 200 with Continued Growth Streak

June 20, 2025 02:46 PM AEST| By Team Kalkine Media

Highlights,Arovella Therapeutics continues gaining traction within the healthcare segment,Long-term revenue trend aligns with rising shareholder interest,Company performance draws attention across,ASX 200,and,All Ordinaries,indices,Arovella Therapeut...

 Ramsay Health Care Faces Extended Downtrend | ASX 50 Healthcare Stock Performance Dips

Ramsay Health Care Faces Extended Downtrend | ASX 50 Healthcare Stock Performance Dips

June 20, 2025 02:40 PM AEST| By Team Kalkine Media

Highlights,Ramsay Health Care's earnings per share experienced extended contraction over recent years,Long-term share performance remained below broader market benchmarks,Dividends have offset some value loss, contributing to higher total shareholder...

 Neurizon Therapeutics Unveils Promising Platform Therapy Potential for ALS and HD, Strengthening ASX200 Biotech Profile

Neurizon Therapeutics Unveils Promising Platform Therapy Potential for ALS and HD, Strengthening ASX200 Biotech Profile

June 20, 2025 11:50 AM AEST| By Team Kalkine Media

Highlights,NUZ-001 shows strong brain penetration in ALS and HD models,Promising neuroprotective effects,demonstrated,in multiple preclinical studies,Platform potential for broader neurodegenerative disorders,Neurizon Therapeutics (ASX:NUZ), a clinic...

 Race Oncology (ASX:RAC) Launches First Patient Dosing in RC220 Trial

Race Oncology (ASX:RAC) Launches First Patient Dosing in RC220 Trial

June 20, 2025 10:51 AM AEST| By Team Kalkine Media

Highlights,RC220 and doxorubicin combination enters Phase 1,No serious toxicities seen in,initial,patient,Expansion planned into Asia, US, and Europe,Race Oncology (ASX:RAC),has marked a pivotal moment in its drug development journey with the success...

 Clarity Pharmaceuticals (ASX:CU6) Advances U.S. Manufacturing in ASX 300 Healthcare Sector

Clarity Pharmaceuticals (ASX:CU6) Advances U.S. Manufacturing in ASX 300 Healthcare Sector

June 19, 2025 06:58 PM AEST| By Team Kalkine Media

Highlights,Clarity Pharmaceuticals (ASX:CU6) belongs to the ASX 300 and operates within the healthcare sector focused on radiopharmaceuticals,Recent manufacturing agreement with SpectronRX supports U.S. readiness for cancer imaging product developmen...

 Promising Start for Race Oncology’s RC220 Trial Among ASX200 Developments

Promising Start for Race Oncology’s RC220 Trial Among ASX200 Developments

June 19, 2025 05:57 PM AEST| By Team Kalkine Media

Highlights,First patient safely dosed with RC220 and doxorubicin,Trial expands across Australia, Hong Kong, and South Korea,Early safety data supports future development milestones,Race Oncology (ASX:RAC),has marked a significant clinical milestone w...

 Formycon AG AGM Greenlights Board Expansion Amid FYB Strategy Shift | SDAX TecDAX Update

Formycon AG AGM Greenlights Board Expansion Amid FYB Strategy Shift | SDAX TecDAX Update

June 19, 2025 03:03 PM AEST| By Team Kalkine Media

Highlights,Formycon AG shareholders approve all agenda items at its annual general meeting,Supervisory Board expanded with re-election of Klaus Röhrig and appointment of Dr. Graham Dixon,Management outlines strategic vision for biosimilar market deve...

 Singular Health (ASX:SHG) Advances US Market Reach with Strategic PNS Deal and Capital Raise

Singular Health (ASX:SHG) Advances US Market Reach with Strategic PNS Deal and Capital Raise

June 19, 2025 03:03 PM AEST| By Team Kalkine Media

Highlights,Singular Health (SHG) inks a $2 million deal to expand its 3D medical imaging platform in the US,Secures $8 million strategic placement to fund expansion and innovation,Partnership with US-based PNS aims to tackle systemic healthcare ineff...

 Orthocell's Remplir Delivers Breakthrough in Nerve Repair, Strengthening Global Ambitions

Orthocell's Remplir Delivers Breakthrough in Nerve Repair, Strengthening Global Ambitions

June 19, 2025 02:32 PM AEST| By Team Kalkine Media

Highlights,Remplir outperforms traditional nerve repair methods,Orthocell’s US market entry gains momentum,Global expansion continues with strong regulatory support,Orthocell Ltd (ASX:OCC) has reported highly encouraging interim results from a pivota...

 Neuren Pharmaceuticals (ASX:NEU) Shows Strong Metrics Despite Market Pullback | ASX 300

Neuren Pharmaceuticals (ASX:NEU) Shows Strong Metrics Despite Market Pullback | ASX 300

June 19, 2025 02:28 PM AEST| By Team Kalkine Media

Highlights,Neuren Pharmaceuticals continues to display robust return on equity within the healthcare sector,Earnings growth remains high compared to broader industry benchmarks,Retained profits signal reinvestment into operations for long-term develo...

 Race Oncology Hits Key Milestone in RC220 Clinical Trial

Race Oncology Hits Key Milestone in RC220 Clinical Trial

June 19, 2025 02:06 PM AEST| By Team Kalkine Media

Highlights,First patient dosed with RC220 + doxorubicin in Phase 1 trial,Trial targets reduced cardiotoxicity in advanced solid tumours,Global sites and strong preclinical backing boost momentum,Race Oncology (ASX:RAC) has reached a major clinical de...

 ASX200 Biotech Breakthrough: Amplia (ASX:ATX) Achieves Rare Success in Pancreatic Cancer Trial

ASX200 Biotech Breakthrough: Amplia (ASX:ATX) Achieves Rare Success in Pancreatic Cancer Trial

June 19, 2025 01:16 PM AEST| By Team Kalkine Media

Highlights,Amplia,Therapeutics reports second complete response in pancreatic cancer trial,Narmafotinib,shows rare efficacy in advanced stage cases,Encouraging progress for ASX-listed biotech in high-mortality cancer treatment,Amplia Therapeutics (AS...

 Why ResMed (ASX:RMD) Is Gaining Attention Among ASX200 Healthcare Stocks

Why ResMed (ASX:RMD) Is Gaining Attention Among ASX200 Healthcare Stocks

June 19, 2025 11:48 AM AEST| By Team Kalkine Media

Highlights,ResMed (RMD) gains over 5% in 2025 YTD.,Strong global footprint and dual growth in medical tech and SaaS.,Healthcare's consistent revenue and ESG relevance,supports,interest.,ResMed (ASX:RMD), a global medical technology company, has seen...

 Cochlear (ASX:COH) Faces Service Division Drag Amid Lowered Guidance

Cochlear (ASX:COH) Faces Service Division Drag Amid Lowered Guidance

June 18, 2025 10:44 PM AEST| By Team Kalkine Media

Highlights,Cochlear Ltd (ASX:COH) operates within the ASX 200 healthcare sector,The company revised its earnings guidance due to weaker service division performance,Launch of Kanso 3 Sound Processor aimed at long-term recovery,Cochlear Ltd (ASX:COH)...

 Healius (ASX:HLS) Sees IVD Growth Momentum in Australia Healthcare Landscape

Healius (ASX:HLS) Sees IVD Growth Momentum in Australia Healthcare Landscape

June 18, 2025 06:13 PM AEST| By Team Kalkine Media

Highlights,Healius Limited (ASX:HLS) operates in the in vitro diagnostics space within the healthcare sector,The stock is part of the ASX 200 and contributes to Australia's growing diagnostic capabilities,Demand for pathology and diagnostic services...

 ASX200 Biotech Player Imugene (ASX:IMU) Strengthens US IP Position with Key Patent Grant

ASX200 Biotech Player Imugene (ASX:IMU) Strengthens US IP Position with Key Patent Grant

June 18, 2025 02:43 PM AEST| By Team Kalkine Media

Highlights,Imugene receives key US patent for innovative cancer therapy.,CF33-CD19 aims to expand CAR T cell treatment to solid tumours.,Supports Imugene’s strategy in global immuno-oncology.,Imugene (ASX:IMU), a clinical-stage immuno-oncology compan...

 Biotech Firm Tetratherix (TTX) Sets ASX Listing Date Amid Expansion Drive

Biotech Firm Tetratherix (TTX) Sets ASX Listing Date Amid Expansion Drive

June 18, 2025 02:40 PM AEST| By Team Kalkine Media

Highlights,Tetratherix Ltd is preparing to debut on the,ASX 200,under the ticker TTX with a listing date set for the end of June.,The biotech company is commercialising its injectable biostealth fluid matrix designed for regenerative medicine.,Funds...

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles






Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.